Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged t-cell receptors

Haematologica

Volumn 99, Issue 1, 2014, Pages 94-102

  Zuurbier, Linda ^a   Gutierrez, Alejandro ^b,c   Mullighan, Charles G ^d   Canté Barrett, Kirsten ^a   Gevaert, A Olivier ^e   De Rooi, Johan ^f   Li, Yunlei ^a   Smits, Willem K ^a   Buijs Gladdines, Jessica G C A M ^a   Sonneveld, Edwin ^g   Look, A Thomas ^b,c   Horstmann, Martin ^h,i   Pieters, Rob ^a,g   Meijerink, Jules P P ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g Dutch Childhood Oncology Group DCOG   (Netherlands)

^h German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL)   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOPHENOTYPING; INFANT; LEUKEMIA, T-CELL; MALE; MEF2 TRANSCRIPTION FACTORS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; TRANSCRIPTOME;

EID: 84892577298     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.090233     Document Type: Article

References (41)

1. Kueh HY, Rothenberg EV. Regulatory gene network circuits underlying T cell development from multipotent progenitors. Wiley Interdiscip Rev Syst Biol Med. 2012;4(1):79-102.
2. Thompson PK, Zuniga-Pflucker JC. On becoming a T cell, a convergence of factors kick it up a Notch along the way. Semin Immunol. 2011;23(5):350-359.
3. Asnafi V, Beldjord K, Boulanger E, Comba B, Le Tutour P, Estienne MH, et al. Analysis of TCR, pT alpha, and RAG-1 in T-acute lym-phoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood. 2003;101(7):2693-2703.
4. Meijerink JP. Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2010;23(3):307-318.
5. Van Vlierberghe P, Pieters R, Beverloo HB, Meijerink JP. Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol. 2008;143(2):153-168.
6. Homminga I, Pieters R, Langerak AW, de Rooi JJ, Stubbs A, Verstegen M, et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell. 2011;19(4):484-497.
7. Dadi S, Le Noir S, Payet-Bornet D, Lhermitte L, Zacarias-Cabeza J, Bergeron J, et al. TLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRalpha gene expression. Cancer Cell. 2012;21(4): 563-576.
8. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, et al. Gene expression signatures define novel onco-genic pathways in T cell acute lymphoblas-tic leukemia. Cancer Cell. 2002;1(1):75-87.
9. Soulier J, Clappier E, Cayuela JM, Regnault A, Garcia-Peydro M, Dombret H, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 2005;106(1): 274-286.
10. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147-156.
11. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481(7380):157-163.
12. Gutierrez A, Dahlberg SE, Neuberg DS, Zhang J, Grebliunaite R, Sanda T, et al. Absence of Biallelic TCR{gamma} Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2010;28(24):3816-23.
13. Asnafi V, Buzyn A, Thomas X, Huguet F, Vey N, Boiron JM, et al. Impact of TCR sta-tus and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood. 2005;105(8):3072-3078.
14. Garand R, Voisin S, Papin S, Praloran V, Lenormand B, Favre M, et al. Characteristics of pro-T ALL subgroups: comparison with late T-ALL. The Groupe d'Etude Immunologique des Leucemies. Leukemia. 1993;7(2):161-167.
15. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenet-ics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114(25):5136-5145.
16. Thiel E, Kranz BR, Raghavachar A, Bartram CR, Loffler H, Messerer D, et al. Prethymic phenotype and genotype of pre-T (CD7?)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood. 1989;73(5):1247-1258.
17. Uckun FM, Gaynon PS, Sensel MG, Nachman J, Trigg ME, Steinherz PG, et al. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent matura-tional stage of T-lineage leukemic blasts: a Children's Cancer Group study. J Clin Oncol. 1997;15(6):2214-2221.
18. Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A, et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood. 2006;107(2):473-479.
19. Inukai T, Kiyokawa N, Campana D, Coustan-Smith E, Kikuchi A, Kobayashi M, et al. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15. Br J Haematol. 2012;156(3):358-365.
20. Ma M, Wang X, Tang J, Xue H, Chen J, Pan C, et al. Early T-cell precursor leukemia: a subtype of high risk childhood acute lym-phoblastic leukemia. Front Med. 2012;6(4): 416-420.
21. Neumann M, Heesch S, Gokbuget N, Schwartz S, Schlee C, Benlasfer O, et al. Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J. 2012;2(1):e55.
22. Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, Haydu JE, Rigo I, Hadler M, et al. ETV6 mutations in early immature human T cell leukemias. J Exp Med. 2011; 208(13):2571-2579.
23. Neumann M, Heesch S, Schlee C, Schwartz S, Gokbuget N, Hoelzer D, et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood. 2013;121(23):4749-4752.
24. Terriou L, Ben Abdelali R, Roumier C, Lhermitte L, de Vos J, Cornillet P, et al. C/EBPA methylation is common in T-ALL but not in M0 AML. Blood. 2009;113(8):1864-1866; author reply 6.
25. Wouters BJ, Jorda MA, Keeshan K, Louwers I, Erpelinck-Verschueren CA, Tielemans D, et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood. 2007;110(10):3706-3714.
26. Yang YL, Hsiao CC, Chen HY, Lin KH, Jou ST, Chen JS, et al. Absence of biallelic TCRgamma deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;58(6):846-851.
27. Callens C, Baleydier F, Lengline E, Ben Abdelali R, Petit A, Villarese P, et al. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol. 2012;30(16):1966-1973.
28. Kamps WA, Bokkerink JP, Hahlen K, Hermans J, Riehm H, Gadner H, et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood. 1999;94(4):1226-1236.
29. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER, et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia. 2002;16(6):1099-1111.
30. Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bokkerink JP, Bruin MC, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol. 2009;10(10):957-966.
31. van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG, et al. Prognostic significance of molecu-lar-cytogenetic abnormalities in pediatric T- ALL is not explained by immunophenotypic differences. Leukemia. 2008;22(1):124-131.
32. Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood. 2003;101(4): 1270-1276.
33. Bergeron J, Clappier E, Cauwelier B, Dastugue N, Millien C, Delabesse E, et al. HOXA cluster deregulation in T-ALL associated with both a TCRD-HOXA and a CALM-AF10 chromosomal translocation. Leukemia. 2006;20(6):1184-1187.
34. Baldus CD, Burmeister T, Martus P, Schwartz S, Gokbuget N, Bloomfield CD, et al. High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol. 2006;24(29):4714-4720.
35. Baldus CD, Martus P, Burmeister T, Schwartz S, Gokbuget N, Bloomfield CD, et al. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lym-phoblastic leukemia with a highly favorable outcome. J Clin Oncol. 2007;25(24):3739-3745.
36. Ben Abdelali R, Asnafi V, Leguay T, Boissel N, Buzyn A, Chevallier P, et al. Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood. 2011;118(19):5099-5107.
37. Novershtern N, Subramanian A, Lawton LN, Mak RH, Haining WN, McConkey ME, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell. 2011;144(2):296-309.
38. Neumann M, Coskun E, Fransecky L, Mochmann LH, Bartram I, Sartangi NF, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One. 2013;8(1):e53190.
39. Mingueneau M, Kreslavsky T, Gray D, Heng T, Cruse R, Ericson J, et al. The transcription-al landscape of alphabeta T cell differentiation. Nat Immunol. 2013;14(6):619-632.
40. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264-278.
41. Homminga I, Vuerhard MJ, Langerak AW, Buijs-Gladdines J, Pieters R, Meijerink J P. Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements. Haematologica. 2012;97(2):258-261.